<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37267401</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>6</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>ABO blood group as a determinant of COVID-19 and Long COVID: An observational, longitudinal, large study.</ArticleTitle><Pagination><StartPage>e0286769</StartPage><MedlinePgn>e0286769</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0286769</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0286769</ELocationID><Abstract><AbstractText Label="BACKGROUND">An association of ABO blood group and COVID-19 remains controversial.</AbstractText><AbstractText Label="METHODS">Following STROBE guidance for observational research, we explored the distribution of ABO blood group in patients hospitalized for acute COVID-19 and in those with Long COVID. Contingency tables were made and risk factors were explored using crude and adjusted Mantle-Haentzel odds ratios (OR and 95% CI).</AbstractText><AbstractText Label="RESULTS">Up to September 2022, there were a total of 5,832 acute COVID-19 hospitalizations in our hospital, corresponding to 5,503 individual patients, of whom blood group determination was available for 1,513 (27.5%). Their distribution by ABO was: 653 (43.2%) group 0, 690 (45.6%) A, 113 (7.5%) B, and 57 (3.8%) AB, which corresponds to the expected frequencies in the general population. In parallel, of 676 patients with Long COVID, blood group determination was available for 135 (20.0%). Their distribution was: 60 (44.4%) from group 0, 61 (45.2%) A, 9 (6.7%) B, and 5 (3.7%) AB. The distribution of the ABO system of Long COVID patients did not show significant differences with respect to that of the total group (p &#x2265; 0.843). In a multivariate analysis adjusting for age, sex, ethnicity, and severity of acute COVID-19 infection, subgroups A, AB, and B were not significantly associated with developing Long COVID with an OR of 1.015 [0.669-1.541], 1.327 [0.490-3.594] and 0.965 [0.453-2.058], respectively. The effect of the Rh+ factor was also not significant 1,423 [0.772-2,622] regarding Long COVID.</AbstractText><AbstractText Label="CONCLUSIONS">No association of any ABO blood subgroup with COVID-19 or developing Long COVID was identified.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2023 Soriano et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Soriano</LastName><ForeName>Joan B</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0001-9740-2994</Identifier><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario de la Princesa, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pel&#xe1;ez</LastName><ForeName>Adri&#xe1;n</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario de la Princesa, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Busquets</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Cell Biomedicine, University of the Balearic Islands, Palma, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodrigo-Garc&#xed;a</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario de la Princesa, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-Urr&#xed;a</LastName><ForeName>Elena &#xc1;valos</ForeName><Initials>E&#xc1;</Initials><Identifier Source="ORCID">0000-0002-9988-4605</Identifier><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario de la Princesa, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alonso</LastName><ForeName>Tamara</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario de la Princesa, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gir&#xf3;n</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario de la Princesa, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valenzuela</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario de la Princesa, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcos</LastName><ForeName>Celeste</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario de la Princesa, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Castillo</LastName><ForeName>Elena</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-4190-6533</Identifier><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario de la Princesa, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ancochea</LastName><ForeName>Julio</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0284-6643</Identifier><AffiliationInfo><Affiliation>Servicio de Neumolog&#xed;a, Hospital Universitario de la Princesa, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000017">ABO Blood-Group System</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012204">Rh-Hr Blood-Group System</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000017" MajorTopicYN="N">ABO Blood-Group System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012204" MajorTopicYN="N">Rh-Hr Blood-Group System</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>14</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37267401</ArticleId><ArticleId IdType="pmc">PMC10237493</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0286769</ArticleId><ArticleId IdType="pii">PONE-D-23-06177</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cohen J, Normile D. New SARS-like virus in China triggers alarm. Science. 2020. Jan 17;367(6475):234&#x2013;235. doi: 10.1126/science.367.6475.234 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.367.6475.234</ArticleId><ArticleId IdType="pubmed">31949058</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Infante A. Aiming for the end of the COVID-19 pandemic: the what, how, who, where, and when. Chin Med J 2023. (in press). doi: 10.1097/CM9.0000000000002149</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000002149</ArticleId><ArticleId IdType="pmc">PMC10106164</ArticleId><ArticleId IdType="pubmed">36752803</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int [accessed on 20 December 2022].</Citation></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021. Jun;594(7862):259&#x2013;264. doi: 10.1038/s41586-021-03553-9 Epub 2021 Apr 22. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise J. Long covid: One in seven children may still have symptoms 15 weeks after infection, data show. BMJ. 2021. Sep 1;374:n2157. doi: 10.1136/bmj.n2157</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2157</ArticleId><ArticleId IdType="pubmed">34470745</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV; WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022. Apr;22(4):e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9 Epub 2021 Dec 21. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes LD, Ingram J, Sculthorpe NF. More Than 100 Persistent Symptoms of SARS-CoV-2 (Long COVID): A Scoping Review. Front Med (Lausanne). 2021. Nov 1;8:750378. doi: 10.3389/fmed.2021.750378 eCollection 2021. .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.750378</ArticleId><ArticleId IdType="pmc">PMC8591053</ArticleId><ArticleId IdType="pubmed">34790680</ArticleId></ArticleIdList></Reference><Reference><Citation>Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C, Ballouz T, et al.. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. JAMA. 2022. Oct 25;328(16):1604&#x2013;1615. doi: 10.1001/jama.2022.18931 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical management of COVID-19: living guideline, 15 September 2022. Geneva: World Health Organization; 2022 (WHO/2019-nCoV/Clinical/2022.2). Licence: CC BY-NC-SA 3.0 IGO. https://www.who.int/publications/i/item/WHO-2019-nCoV-Clinical-2022.2 [accessed on 14 December 2022].</Citation></Reference><Reference><Citation>Severe Covid-19 GWAS Group, Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, et al.. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med. 2020. Oct 15;383(16):1522&#x2013;1534. doi: 10.1056/NEJMoa2020283 Epub 2020 Jun 17. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2020283</ArticleId><ArticleId IdType="pmc">PMC7315890</ArticleId><ArticleId IdType="pubmed">32558485</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Yang Y, Huang H, Li D, Gu D, Lu X, et al.. Relationship Between the ABO Blood Group and the Coronavirus Disease 2019 (COVID-19) Susceptibility. Clin Infect Dis. 2021. Jul 15;73(2):328&#x2013;331. doi: 10.1093/cid/ciaa1150 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1150</ArticleId><ArticleId IdType="pmc">PMC7454371</ArticleId><ArticleId IdType="pubmed">32750119</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharjee S, Banerjee M, Pal R. ABO blood groups and severe outcomes in COVID-19: A meta-analysis. Postgrad Med J. 2022. Mar;98(e2):e136&#x2013;e137. doi: 10.1136/postgradmedj-2020-139248 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/postgradmedj-2020-139248</ArticleId><ArticleId IdType="pubmed">35232874</ArticleId></ArticleIdList></Reference><Reference><Citation>Balaouras G, Eusebi P, Kostoulas P. Systematic review and meta-analysis of the effect of ABO blood group on the risk of SARS-CoV-2 infection. PLoS One. 2022. Jul 28;17(7):e0271451. doi: 10.1371/journal.pone.0271451 eCollection 2022. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0271451</ArticleId><ArticleId IdType="pmc">PMC9333251</ArticleId><ArticleId IdType="pubmed">35901063</ArticleId></ArticleIdList></Reference><Reference><Citation>Abuawwad MT, Taha MJJ, Abu-Ismail L, Alrubasy WA, Sameer SK, Abuawwad IT, et al.. Effects of ABO blood groups and RH-factor on COVID-19 transmission, course and outcome: A review. Front Med (Lausanne). 2023. Jan 12;9:1045060. doi: 10.3389/fmed.2022.1045060 eCollection 2022. .</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.1045060</ArticleId><ArticleId IdType="pmc">PMC9878296</ArticleId><ArticleId IdType="pubmed">36714134</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Latz CA, DeCarlo CS, Lee S, Png CYM, Kibrik P, et al.. Relationship between blood type and outcomes following COVID-19 infection. Semin Vasc Surg. 2021. Sep;34(3):125&#x2013;131. doi: 10.1053/j.semvascsurg.2021.05.005 Epub 2021 Jul 18. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.semvascsurg.2021.05.005</ArticleId><ArticleId IdType="pmc">PMC8286549</ArticleId><ArticleId IdType="pubmed">34642032</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooling L. Blood Groups in Infection and Host Susceptibility. Clin Microbiol Rev. 2015. Jul;28(3):801&#x2013;70. doi: 10.1128/CMR.00109-14 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00109-14</ArticleId><ArticleId IdType="pmc">PMC4475644</ArticleId><ArticleId IdType="pubmed">26085552</ArticleId></ArticleIdList></Reference><Reference><Citation>Anstee DJ. The relationship between blood groups and disease. Blood. 2010. Jun 10;115(23):4635&#x2013;43. doi: 10.1182/blood-2010-01-261859 Epub 2010 Mar 22. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-01-261859</ArticleId><ArticleId IdType="pubmed">20308598</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng Y, Cheng G, Chui CH. ABO blood group and susceptibility to severe acute respiratory syndrome. JAMA. 2005. Mar 23;293(12):1450&#x2013;1. doi: 10.1001/jama.293.12.1450-c</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.293.12.1450-c</ArticleId><ArticleId IdType="pubmed">15784866</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindesmith L, Moe C, Marionneau S. Human susceptibility and resistance to Norwalk virus infection. Nat Med. 2003. May;9(5):548&#x2013;53. doi: 10.1038/nm860 Epub 2003 Apr 14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm860</ArticleId><ArticleId IdType="pubmed">12692541</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang DS, Chen DL, Ren C. ABO blood group, hepatitis B viral infection and risk of pancreatic cancer. Int J Cancer. 2012. Jul 15;131(2):461&#x2013;8. doi: 10.1002/ijc.26376 Epub 2011 Nov 30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.26376</ArticleId><ArticleId IdType="pubmed">21858814</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronstein-Wiedemann R, Stadtm&#xfc;ller M, Traikov S, Georgi M, Teichert M, Yosef H, et al.. SARS-CoV-2 Infects Red Blood Cell Progenitors and Dysregulates Hemoglobin and Iron Metabolism. Stem Cell Rev Rep. 2022. Jun;18(5):1809&#x2013;1821. doi: 10.1007/s12015-021-10322-8 Epub 2022 Feb 18. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12015-021-10322-8</ArticleId><ArticleId IdType="pmc">PMC8856880</ArticleId><ArticleId IdType="pubmed">35181867</ArticleId></ArticleIdList></Reference><Reference><Citation>Nafakhi A, Rabeea IS, Al-Darraji R, Nafakhi H, Mechi A, Al-Khalidi A, et al.. Association of ABO blood group with in-hospital adverse outcome and long term persistent symptoms of COVID-19 infection: A single-center longitudinal observational study. Health Sci Rep. 2022. May 23;5(3):e656. doi: 10.1002/hsr2.656 eCollection 2022 May. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hsr2.656</ArticleId><ArticleId IdType="pmc">PMC9125875</ArticleId><ArticleId IdType="pubmed">35620543</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengelloun AK, Ortega GJ, Ancochea J, Sanz-Garcia A, Rodr&#xed;guez-Serrano DA, Fern&#xe1;ndez-Jim&#xe9;nez G, et al.. Usefulness of the CONUT index upon hospital admission as a potential prognostic indicator of COVID-19 health outcomes. Chin Med J (Engl). 2021. Oct 26;135(2):187&#x2013;193. doi: 10.1097/CM9.0000000000001798 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000001798</ArticleId><ArticleId IdType="pmc">PMC8769140</ArticleId><ArticleId IdType="pubmed">34711718</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengelloun AK, Ortega GJ, Soriano JB; en nombre del Grupo de Investigaci&#xf3;n Coronita Princesa. Impact of COVID-19 on the Latin American population in Spain during the first and second waves. Med Clin (Barc). 2021. Nov 26;157(10):496&#x2013;497. doi: 10.1016/j.medcli.2021.04.024 Epub 2021 May 27. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medcli.2021.04.024</ArticleId><ArticleId IdType="pmc">PMC8156910</ArticleId><ArticleId IdType="pubmed">34120757</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008. Apr;61(4):344&#x2013;9. doi: 10.1016/j.jclinepi.2007.11.008 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2007.11.008</ArticleId><ArticleId IdType="pubmed">18313558</ArticleId></ArticleIdList></Reference><Reference><Citation>Distribuci&#xf3;n de los grupos sangu&#xed;neos en Espa&#xf1;a. Consejo Superior de Investigaciones Cient&#xed;ficas. Instituto Juan Sebasti&#xe1;n Elcano, Madrid. 1947.</Citation></Reference><Reference><Citation>Google grupos sangu&#xed;neo en Espa&#xf1;a. https://www.google.com/search?q=grupos+sangu%C3%ADneo+espa%C3%B1a&amp;biw=1462&amp;bih=660&amp;ei=RcmGY-OiOKHAkdUPmNiF-AE&amp;ved=0ahUKEwij2bzl9tT7AhUhYKQEHRhsAR8Q4dUDCA8&amp;uact=5&amp;oq=grupos+sangu%C3%ADneo+espa%C3%B1a&amp;gs_lcp=Cgxnd3Mtd2l6LXNlcnAQAzIHCAAQgAQQDTIICAAQBxAeEAoyCAgAEAUQBxAeOgoIABBHENYEELADOgUIABCABDoGCAAQBRAeSgQIQRgASgQIRhgAUIgFWOMGYOASaAJwAHgAgAFdiAGtAZIBATKYAQCgAQHIAQjAAQE&amp;sclient=gws-wiz-serp [accessed on 14 December 2022].</Citation></Reference><Reference><Citation>Burke MJ, Del Rio C. Long COVID has exposed medicine&#x2019;s blind-spot. Lancet Infect Dis. 2021. Aug;21(8):1062&#x2013;1064. doi: 10.1016/S1473-3099(21)00333-9 Epub 2021 Jun 18. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00333-9</ArticleId><ArticleId IdType="pmc">PMC8213360</ArticleId><ArticleId IdType="pubmed">34153235</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunhofer V, Weidner L, Hoeggerl AD, Zimmermann G, Badstuber N, Grabmer C, et al.. Persistence of Naturally Acquired and Functional SARS-CoV-2 Antibodies in Blood Donors One Year after Infection. Viruses. 2022. Mar 18;14(3):637. doi: 10.3390/v14030637 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14030637</ArticleId><ArticleId IdType="pmc">PMC8953712</ArticleId><ArticleId IdType="pubmed">35337044</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward SE, O&#x2019;Sullivan JM, O&#x2019;Donnell JS. The relationship between ABO blood group, von Willebrand factor, and primary hemostasis. Blood. 2020. Dec 17;136(25):2864&#x2013;2874. doi: 10.1182/blood.2020005843 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020005843</ArticleId><ArticleId IdType="pmc">PMC7751360</ArticleId><ArticleId IdType="pubmed">32785650</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortel TL, Berliner N. Introduction to a review series on COVID-19 and the hematologist. Blood. 2022. Jul 21;140(3):163&#x2013;164. doi: 10.1182/blood.2022017072 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2022017072</ArticleId><ArticleId IdType="pmc">PMC9170282</ArticleId><ArticleId IdType="pubmed">35661194</ArticleId></ArticleIdList></Reference><Reference><Citation>Candido KL, Eich CR, de Fari&#xf1;a LO, Kadowaki MK, da Concei&#xe7;&#xe3;o Silva JL, et al.. Spike protein of SARS-CoV-2 variants: a brief review and practical implications. Braz J Microbiol. 2022. Sep;53(3):1133&#x2013;1157. doi: 10.1007/s42770-022-00743-z Epub 2022 Apr 9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s42770-022-00743-z</ArticleId><ArticleId IdType="pmc">PMC8994061</ArticleId><ArticleId IdType="pubmed">35397075</ArticleId></ArticleIdList></Reference><Reference><Citation>Consortium AA Structural and functional comparison of SARS-CoV-2-spike receptor binding domain produced in Pichia pastoris and mammalian cells. Sci Rep. 2020;10:21779. doi: 10.1038/s41598-020-78711-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-78711-6</ArticleId><ArticleId IdType="pmc">PMC7732851</ArticleId><ArticleId IdType="pubmed">33311634</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomson EC, Rosen LE, Shepherd JG, Spreafico R, da Silva Filipe A, Wojcechowskyj JA, et al.. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell. 2021;184:1171&#x2013;1187.e20. doi: 10.1016/j.cell.2021.01.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.037</ArticleId><ArticleId IdType="pmc">PMC7843029</ArticleId><ArticleId IdType="pubmed">33621484</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillon P, Cl&#xe9;ment M, S&#xe9;bille V, Rivain J-G, Chou C-F, Ruvo&#xeb;n-Clouet N, et al.. Inhibition of the interaction between the SARS-CoV Spike protein and its cellular receptor by anti-histo-blood group antibodies. Glycobiology. 2008. Dec;18(12):1085&#x2013;93. doi: 10.1093/glycob/cwn093 Epub 2008 Sep 25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/glycob/cwn093</ArticleId><ArticleId IdType="pmc">PMC7108609</ArticleId><ArticleId IdType="pubmed">18818423</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou C-F, Shen S, Tan Y-J, Fielding BC, Tan THP, Fu J, et al.. A novel cell-based binding assay system reconstituting interaction between SARS-CoV S protein and its cellular receptor. J Virol Methods. 2005. Jan;123(1):41&#x2013;8. doi: 10.1016/j.jviromet.2004.09.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2004.09.008</ArticleId><ArticleId IdType="pmc">PMC7112911</ArticleId><ArticleId IdType="pubmed">15582697</ArticleId></ArticleIdList></Reference><Reference><Citation>Marionneau S, Cailleau-Thomas A, Rocher J, Le Moullac-Vaidye B, Ruvo&#xeb;n-clouet N, Cl&#xe9;ment M, et al.. ABH and Lewis histo-blood group antigens, a model for the meaning of oligosaccharide diversity in the face of a changing world. Biochimie. 2001. Jul;83(7):565&#x2013;73. doi: 10.1016/s0300-9084(01)01321-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0300-9084(01)01321-9</ArticleId><ArticleId IdType="pubmed">11522384</ArticleId></ArticleIdList></Reference><Reference><Citation>Miotto M, Di Rienzo L, Gosti G, Milanetti E, Ruocco G. Does blood type affect the COVID-19 infection pattern? PLoS One. 2021. May 13;16(5):e0251535. doi: 10.1371/journal.pone.0251535 eCollection 2021. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0251535</ArticleId><ArticleId IdType="pmc">PMC8118288</ArticleId><ArticleId IdType="pubmed">33984040</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund LC, Hallas J, Nielsen H, Koch A, Mogensen SH, Brun NC, et al.. Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study. Lancet Infect Dis. 2021. Oct;21(10):1373&#x2013;1382. doi: 10.1016/S1473-3099(21)00211-5 Epub 2021 May 10. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00211-5</ArticleId><ArticleId IdType="pmc">PMC8110209</ArticleId><ArticleId IdType="pubmed">33984263</ArticleId></ArticleIdList></Reference><Reference><Citation>Pe&#xf1;alvo JL, Mertens E, Ademovi&#x107; E, Akgun S, Baltazar AL, Buonfrate D, et al.. Unravelling data for rapid evidence-based response to COVID-19: a summary of the unCoVer protocol. BMJ Open. 2021. Nov 18;11(11):e055630. doi: 10.1136/bmjopen-2021-055630 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-055630</ArticleId><ArticleId IdType="pmc">PMC8602928</ArticleId><ArticleId IdType="pubmed">34794999</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavriilaki E, Kokoris S. COVID-19 sequelae: can long-term effects be predicted? Lancet Infect Dis. 2022. Dec;22(12):1651&#x2013;1652. doi: 10.1016/S1473-3099(22)00529-1 Epub 2022 Aug 26. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00529-1</ArticleId><ArticleId IdType="pmc">PMC9411257</ArticleId><ArticleId IdType="pubmed">36030797</ArticleId></ArticleIdList></Reference><Reference><Citation>Houchen-Wolloff L, Poinasamy K, Holmes K, Tarpey M, Hastie C, Raihani K, et al.. Joint patient and clinician priority setting to identify 10 key research questions regarding the long-term sequelae of COVID-19. Thorax. 2022. Jul;77(7):717&#x2013;720. doi: 10.1136/thoraxjnl-2021-218582 Epub 2022 Mar 30. .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2021-218582</ArticleId><ArticleId IdType="pmc">PMC9209667</ArticleId><ArticleId IdType="pubmed">35354642</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>